Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

被引：0

作者：

Rodriguez-Otero, Paula ^{[1
]}

Joseph, Nisha ^{[2
]}

Kumar, Shaji ^{[3
]}

Leleu, Xavier ^{[4
]}

Manier, Salomon ^{[5
]}

Dimopoulos, Meletios ^{[6
]}

Mateos, Maria-Victoria ^{[7
]}

Oriol, Albert ^{[8
,9
]}

Bumma, Naresh ^{[10
]}

Gong, Weiying ^{[11
]}

Roy, Pourab ^{[11
]}

Lorenc, Karen Rodriguez ^{[11
]}

Kroog, Glenn ^{[11
]}

Sarkaria, Shawn ^{[11
]}

机构：

[1] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[3] Mayo Clin, Rochester, MN USA

[4] Hosp Mileterie, Poitiers, France

[5] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[6] Natl & Kapodistrian Univ Athens, Athens, Greece

[7] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[8] Catalan Inst Oncol, Hosp Germans Trias i Pujol, Badalona, Spain

[9] Josep Carreras Inst, Hosp Germans Trias i Pujol, Badalona, Spain

[10] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-046

引用

页码：S60 / S60

页数：1

共 50 条

[1] Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Rodriguez Otero, Paula
Joseph, Nisha S.
Kumar, Shaji K.
Lee, Hans C.
Leleu, Xavier
Manier, Salomon
Dimopoulos, Meletios A.
Victoria Mateos, Maria
Oriol, Albert
Bumma, Naresh
Gong, Weiying
Roy, Pourab
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Sarkaria, Shawn M.
BLOOD, 2022, 140 : 4444 - 4446
[2] Immunotherapy-Based Treatment Options in Relapsed/Refractory Multiple Myeloma: Updated Results from Phase 1b Trial of Combination Therapy with Daratumumab and Teclistamab (BCMAxCD3 Bispecific Antibody)
Waesch, R.
Rodriguez-Otero, P.
D'Souza, A.
Reece, D.
Van De Donk, N. W.
Chari, A.
Krishnan, A.
Martin, T.
Mateos, M., V
Morillo, D.
Hurd, D.
Rosinol, L.
Balari, A. S.
Vishwamitra, D.
Wang, Lin S. X.
Prior, T.
Vandenberk, L.
Smit, Damiette M. -A
Oriol, A.
Dholaria, B.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 249
[3] Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
Ferreri, Christopher J.
Quatela, Steven E.
Aina, Sean
Roy, Pourab
Boyapati, Anita
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Orlowski, Robert Z.
BLOOD, 2022, 140 : 10129 - 10130
[4] Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
Bumma, Naresh
Richter, Joshua
Brayer, Jason
Zonder, Jeffrey A.
Dhodapkar, Madhav
Shah, Mansi R.
Hoffman, James E.
Mawad, Raya
Maly, Joseph J.
Lentzsch, Suzanne
Suvannasankha, Attaya
Roy, Pourab
Dey, Jyotirmoy
Chokshi, Dhruti
Boyapati, Anita
Visich, Jenn
Houvras, Yariv
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Jagannath, Sundar
BLOOD, 2022, 140 : 10140 - 10141
[5] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Merryman, Reid W.
Redd, Robert A.
Freedman, Arnold S.
Ahn, Inhye E.
Brown, Jennifer R.
Crombie, Jennifer L.
Davids, Matthew S.
Fisher, David C.
Jacobsen, Eric D.
Kim, Austin I.
LaCasce, Ann S.
Ng, Samuel
Odejide, Oreofe O.
Parry, Erin M.
Isufi, Iris
Kline, Justin
Cohen, Jonathon B.
Mehta-Shah, Neha
Bartlett, Nancy L.
Mei, Matthew
Kuntz, Thomas M.
Wolff, Jacquelyn
Rodig, Scott J.
Armand, Philippe
Jacobson, Caron A.
ANNALS OF HEMATOLOGY, 2024, 103 (01) : 185 - 198
[6] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Reid W. Merryman
Robert A. Redd
Arnold S. Freedman
Inhye E. Ahn
Jennifer R. Brown
Jennifer L. Crombie
Matthew S. Davids
David C. Fisher
Eric D. Jacobsen
Austin I. Kim
Ann S. LaCasce
Samuel Ng
Oreofe O. Odejide
Erin M. Parry
Iris Isufi
Justin Kline
Jonathon B. Cohen
Neha Mehta-Shah
Nancy L. Bartlett
Matthew Mei
Thomas M. Kuntz
Jacquelyn Wolff
Scott J. Rodig
Philippe Armand
Caron A. Jacobson
Annals of Hematology, 2024, 103 : 185 - 198
[7] Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
Zonder, Jeffrey
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Cronier, Damien
Houvras, Yariv
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S35
[8] Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMAxCD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma
Schjesvold, Fredrik
Spencer, Andrew
Cohen, Yael C.
Ocio, Enrique M.
Lopez-Pardo, Jordi
Cafro, Anna Maria
Callander, Natalie S.
Kaufman, Jonathan L.
Mohan, Meera
Wermke, Martin
Doki, Noriko
Kan, Rebecca
Kulec, Karolina
Trabucco, Gina
Ye, Stan
Sechaud, Romain
Quadt, Cornelia
Chawla, Raghav
Raab, Marc S.
BLOOD, 2023, 142
[9] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Zonder, Jeffrey A.
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Cronier, Damien
Houvras, Yariv
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S406 - S407
[10] A novel Immunotherapy Combination in relapsed/refractory Multiple Myeloma: Updated Analysis of Phase 1b Data for Talquetamab, a GPRC5DxCD3 bispecific Antibody, in Combination with Daratumumab
Kortuem, K. M.
Bahlis, N.
Mateos, M. -V.
Weisel, K.
Dholaria, B.
Garfall, A.
Goldschmidt, H.
Martin, T.
Morillo, D.
Reece, D.
Hurd, D.
Rodriguez-Otero, P.
Bhutani, M.
D'Souza, A.
Oriol, A.
Askari, E.
San-Miguel, J.
van de Donk, N.
Vishwamitra, D.
Lin, Wang S. X.
Prior, T.
Vandenberk, L.
Smit, Damiette M. -A.
Goldberg, J.
Waesch, R.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 144 - 145

← 1 2 3 4 5 →